Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), ANI Pharmaceuticals (ANIP) and ALX Oncology Holdings (ALXO)

Tipranks - Tipranks - Tue Mar 3, 7:17AM CST

Analysts fell to the sidelines weighing in on Amgen (AMGN – Research Report), ANI Pharmaceuticals (ANIP – Research Report) and ALX Oncology Holdings (ALXO – Research Report) with neutral ratings, indicating that the experts are neither bullish nor bearish on the stocks.

Claim 70% Off TipRanks Premium

Amgen (AMGN)

In a report released today, Gregory Renza from Truist Financial maintained a Hold rating on Amgen. The company’s shares closed last Friday at $388.16.

According to TipRanks.com, Renza is a 5-star analyst with an average return of 18.7% and a 47.9% success rate. Renza covers the Healthcare sector, focusing on stocks such as Perspective Therapeutics, Abivax SA Sponsored ADR, and Viridian Therapeutics. ;'>

Currently, the analyst consensus on Amgen is a Moderate Buy with an average price target of $370.45, implying a -2.3% downside from current levels. In a report issued on February 19, Barclays also initiated coverage with a Hold rating on the stock with a $350.00 price target.

See today’s best-performing stocks on TipRanks >>

ANI Pharmaceuticals (ANIP)

In a report released today, Les Sulewski from Truist Financial maintained a Hold rating on ANI Pharmaceuticals. The company’s shares closed last Friday at $73.90.

According to TipRanks.com, Sulewski is a 4-star analyst with an average return of 7.8% and a 42.5% success rate. Sulewski covers the Healthcare sector, focusing on stocks such as Collegium Pharmaceutical, Bausch Health Companies, and Amneal Pharmaceuticals. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for ANI Pharmaceuticals with a $115.00 average price target, representing a 50.8% upside. In a report issued on February 27, TipRanks – DeepSeek also downgraded the stock to Hold with a $83.00 price target.

ALX Oncology Holdings (ALXO)

LifeSci Capital analyst Sam Slutsky maintained a Hold rating on ALX Oncology Holdings today. The company’s shares closed last Friday at $2.11, close to its 52-week low of $0.65.

According to TipRanks.com, Slutsky is a top 100 analyst with an average return of 43.6% and a 53.4% success rate. Slutsky covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, ArriVent BioPharma, Inc., and Abivax SA Sponsored ADR. ;'>

Currently, the analyst consensus on ALX Oncology Holdings is a Moderate Buy with an average price target of $4.00.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).